NanoBio Corp.
NanoBio Initiates FDA Approved Clinical Trial for Adjuvanted Intranasal Influenza Vaccine
Published in Bioterrorism Week, May 4th, 2009
NanoBio Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. NB-1008 uses a novel nanoemulsion-based adjuvant to achieve a robust immune response using only a small fraction of the antigen required by currently available injectable vaccines. In numerous animal studies, NB-1008 has demonstrated robust mucosal, systemic and cellular immunity without inflammation or safety concerns.
The underlying technology for NB-1008 is NanoBio’s NanoStatTM platform, which employs a nanoemulsion that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Bioterrorism Week
Source: Bioterrorism Week (2009-05-04)
More Articles from Bioterrorism Week
- Anthrax
New findings from Food & Drug Administration describe advances in anthrax - Biological Warfare
Research in the area of biological warfare reported from State University of New York - Public Health
Data on public health published by L. Bedsworth and colleagues - Anthrax Immunology
New anthrax immunology study findings recently were reported by researchers at University of California, Department of Microbiology-Immunology - Homeland Security
Studies from Stanford University in the area of homeland security published - Life Sciences
Research from Drexel University in the area of life sciences published - More from this issue of Bioterrorism Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
